Hasmik Samvel Harutyunyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hasmik Samvel Harutyunyan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Gayane Sargis Vardanyan
Department of Biochemistry, Yerevan State Medical University, Yerevan, Armenia
2 shared publications - Konstantin Yenkoyan
Neuroscience Laboratory, Cobrain Center, Yerevan State Medical University after M. Heratsi, 2 Koryun, 0025, Yerevan, Armenia.
2 shared publications - Michail Iosif Aghajanov
Department of Biochemistry, Yerevan State Medical University, Yerevan, Armenia
2 shared publications A. A. Grigoryan
Yerevan State Medical University
1 shared publication- Alexey A. Lagunin
Department for Bioinformatics, Institute of Biomedical Chemistry, 119121 Moscow, Russia
1 shared publication Alla Shaljyan
Department of Biochemistry, Yerevan State Medical University Named After M. Heratsi, Yerevan, Armenia
1 shared publication
Latest Publications
- 22 March 2026
- Published by Elsevier in Neuroscience
- Vol. 603, 57-68
Neurobiological links between Alzheimer’s disease and reward system dysfunction
- 22 March 2026
- Published by Elsevier in Neuroscience
- Vol. 603, 57-68
Neurobiological links between Alzheimer’s disease and reward system dysfunction
- 1 July 2023
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 53 (6) , 907-916
Diet-based avoidance implications in rats in the conditional association with aversive stimuli
- 1 July 2023
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- Vol. 53 (6) , 907-916
Diet-based avoidance implications in rats in the conditional association with aversive stimuli
- Open Access
- 30 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9482
Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies
Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development.
- 30 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9482
Open AccessTowards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies
Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development.
- 1 March 2023
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 17 (1) , 111-119
Repetitive Noxious Stimulation with Formalin, Capsaicin, and Freund’s Adjuvant Facilitates Monitoring of the Peripheral and Central Pain Effects
Pain is one of the most frequent symptoms accompanying diseases. Every type of pain invokes various molecular mechanisms leading to the central effects, and hence the pain response. The plasticity of the nervous system is a unique property enabling it to change the number and quality of neural connections in order to adapt to the environment. This property is the basis of memory, particularly “pain memory”. The formalin test is widely used as an experimental model of biphasic pain in laboratory animals. We supposed that adding the second injection of a noxious agent to the classical test will enhance the pain response and let us observe plastic changes in the central nervous system and in the periphery. The contralateral repetitive injection of formalin and capsaicin to the rat hind paw revealed an increase in pain score in Phase 1 and a decrease in Phase 2. In Freund’s adjuvant injected group the pain score in both phases was increased. Different patterns of spinal cord neuronal activity were observed in formalin, capsaicin, and Freund’s adjuvant injections. Contralateral repetitive administration of formalin and capsaicin, but not Freund’s adjuvant revealed a “pain memory”, a pain response in previously injected but unaffected in the second injection paw. Analysis of the “pain memory” based on our previous studies revealed its overall central character and lack of association with inflammation. Investigations of mechanisms underlying each type of pain and deep analysis of pain memory may open new perspectives to prevent and treat pain.
- 1 March 2023
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 17 (1) , 111-119
Repetitive Noxious Stimulation with Formalin, Capsaicin, and Freund’s Adjuvant Facilitates Monitoring of the Peripheral and Central Pain Effects
Pain is one of the most frequent symptoms accompanying diseases. Every type of pain invokes various molecular mechanisms leading to the central effects, and hence the pain response. The plasticity of the nervous system is a unique property enabling it to change the number and quality of neural connections in order to adapt to the environment. This property is the basis of memory, particularly “pain memory”. The formalin test is widely used as an experimental model of biphasic pain in laboratory animals. We supposed that adding the second injection of a noxious agent to the classical test will enhance the pain response and let us observe plastic changes in the central nervous system and in the periphery. The contralateral repetitive injection of formalin and capsaicin to the rat hind paw revealed an increase in pain score in Phase 1 and a decrease in Phase 2. In Freund’s adjuvant injected group the pain score in both phases was increased. Different patterns of spinal cord neuronal activity were observed in formalin, capsaicin, and Freund’s adjuvant injections. Contralateral repetitive administration of formalin and capsaicin, but not Freund’s adjuvant revealed a “pain memory”, a pain response in previously injected but unaffected in the second injection paw. Analysis of the “pain memory” based on our previous studies revealed its overall central character and lack of association with inflammation. Investigations of mechanisms underlying each type of pain and deep analysis of pain memory may open new perspectives to prevent and treat pain.
- 12 October 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 12 (20) , 1865-1884
Neurochemical Regulators of Food Behavior for Pharmacological Treatment of Obesity: Current Status and Future Prospects
In recent decades, obesity has become a pandemic disease and appears to be an ultimate medical and social problem. Existing antiobesity drugs show low efficiency and a wide variety of side effects....
- 12 October 2020
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 12 (20) , 1865-1884
Neurochemical Regulators of Food Behavior for Pharmacological Treatment of Obesity: Current Status and Future Prospects
In recent decades, obesity has become a pandemic disease and appears to be an ultimate medical and social problem. Existing antiobesity drugs show low efficiency and a wide variety of side effects....
- 1 April 2017
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 11 (2) , 176-184
The effect of peripheral analgesia on “pain memory” changes in modified formalin test
Peripheral tissue damage or nerve injury often leads to development of pathological pain processes, such as spontaneous pain, hyperalgesia and allodynia that persist for years or decades after all possible tissue healing has occurred. The modification of classic formalin test with two subsequent injections of formalin can be useful to investigate central mechanisms of “pain memory”. To evaluate the effect of analgesia of periphery on central pathways of nociception we used four groups of analgesics: a local anaesthetic-lidocaine, NSAID-diclofenac, a mu-opioid receptor agonist-DAMGO, anticonvulsant with chronic pain-relieving action-gabapentin. We studied the impact of analgesic drugs on acute and chronic pain conditions taking as a basis c-Fos as a pain intensity marker.
- 1 April 2017
- Published by Pleiades Publishing Ltd in Neurochemical Journal
- Vol. 11 (2) , 176-184
The effect of peripheral analgesia on “pain memory” changes in modified formalin test
Peripheral tissue damage or nerve injury often leads to development of pathological pain processes, such as spontaneous pain, hyperalgesia and allodynia that persist for years or decades after all possible tissue healing has occurred. The modification of classic formalin test with two subsequent injections of formalin can be useful to investigate central mechanisms of “pain memory”. To evaluate the effect of analgesia of periphery on central pathways of nociception we used four groups of analgesics: a local anaesthetic-lidocaine, NSAID-diclofenac, a mu-opioid receptor agonist-DAMGO, anticonvulsant with chronic pain-relieving action-gabapentin. We studied the impact of analgesic drugs on acute and chronic pain conditions taking as a basis c-Fos as a pain intensity marker.